AZNAstraZenecaSigning up patients
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
HER2-positive Gastric Cancer · Gastroesophageal Junction Adenocarcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 840 (planned)
- Started
- Mar 1, 2025
- Main results expected
- Apr 27, 2029
- Fully finished
- Dec 9, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival (PFS)
Measured over: Up to approximately 6 years
Overall Survival (OS)
Measured over: Up to approximately 6 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06764875 · record last updated 2026-10-16 · checked 2026-11-09 15:47 UTC